Maca

Maca macamides modulate the HPA axis via serotonergic (5-HT) pathways in the hypothalamic paraventricular nucleus, reducing ACTH and cortisol. This serotonergic pathway modulation may enhance the effects of SSRIs/SNRIs. A case report described possible CYP3A4 inhibition by maca leading to elevated mianserin (tetracyclic antidepressant) plasma levels in a 64-year-old male patient.

Monitor for additive antidepressant effects or serotonin-related adverse effects when combining maca with antidepressants. Reassess antidepressant dosing if maca is added to a regimen. Exercise particular caution with MAOIs.

Preclinical screening studies (PAMPA-coupled human liver microsome assay) suggest maca root extract may inhibit CYP3A4 in vitro. Additionally, maca modulates liver CYP450 activity indirectly by reducing ACTH and cortisol via the HPA/5-HT axis. A case report described maca potentially increasing plasma mianserin levels consistent with CYP3A4 inhibition.

Exercise caution with narrow-therapeutic-index CYP3A4 substrates (cyclosporine, tacrolimus, certain statins). Monitor for signs of increased drug effect. Additional clinical pharmacokinetic data are needed to determine the clinical significance of this interaction.

Maca has demonstrated antihypertensive properties in preclinical studies and contributes to blood pressure lowering via nitric oxide pathway modulation and possible diuretic effects. While clinical data are limited, the potential for additive hypotensive effects exists when maca is combined with antihypertensive medications.

Monitor blood pressure regularly when adding maca to an antihypertensive regimen. Inform patients about potential for dizziness or lightheadedness. The interaction is low risk overall but warrants awareness in patients prone to hypotension.

Maca has demonstrated effects on insulin sensitivity and glucose metabolism in preclinical models. Co-administration with antidiabetic medications may contribute to additive hypoglycemic effects, particularly with insulin and insulin secretagogues.

Monitor blood glucose in diabetic patients using maca supplements. Educate patients about signs of hypoglycemia (dizziness, sweating, tremors). No dose adjustment is routinely needed, but awareness of potential additive hypoglycemic effect is warranted.

Maca root contains glucosinolates and other phytochemicals that may exert mild estrogenic or estrogen-modulating effects. Maca has demonstrated efficacy in reducing menopausal symptoms (hot flashes, mood changes), suggesting estrogen pathway activity. Co-administration with exogenous estrogen may produce additive or synergistic hormonal effects.

Use caution when combining maca with estrogen-containing medications. Women with hormone-sensitive conditions (estrogen receptor-positive breast cancer, endometriosis, uterine fibroids) should consult their physician before using maca supplements.

Maca has demonstrated antithrombotic properties in preclinical studies, related to its glucosinolate and polyphenol content. This may contribute to additive antiplatelet or anticoagulant effects when combined with anticoagulant medications. The interaction is primarily pharmacodynamic and low risk at typical supplemental doses.

Exercise caution in patients on anticoagulant or antiplatelet therapy. Monitor for signs of increased bleeding. Discontinue maca supplements at least 1-2 weeks before elective surgical procedures as a precautionary measure.

Maca (Lepidium meyenii) contains glucosinolates, which are goitrogenic compounds that may interfere with thyroid hormone synthesis by competing with iodide uptake in the thyroid gland at high doses or in iodine-deficient individuals. Clinical studies have also demonstrated that maca modulates pituitary hormone secretion including T3 and TSH suppression, which could alter the required dose of thyroid replacement therapy or the effectiveness of anti-thyroid drugs.

Patients with hypothyroidism or hyperthyroidism should consult their physician before using maca. Monitor thyroid function tests (TSH, free T4) if maca is initiated or discontinued in patients on levothyroxine or anti-thyroid medications. Advise adequate dietary iodine intake. Space maca administration at least 4 hours apart from levothyroxine to avoid absorption interference.

Maca influences the hypothalamic-pituitary-adrenal (HPA) axis, with clinical evidence demonstrating suppression of ACTH and cortisol secretion in postmenopausal women. Co-administration with exogenous corticosteroids may alter HPA axis dynamics, potentially affecting adrenal recovery or stress responsiveness in patients on long-term steroid therapy or in those being tapered off glucocorticoids.

Monitor adrenal function parameters in patients on chronic corticosteroid therapy who also use maca. Exercise particular caution in patients being tapered off corticosteroids, where adrenal recovery is critical. Maca-mediated HPA modulation may complicate the cortisol taper process and mask adrenal insufficiency symptoms.

Macamides (benzylamine fatty acid amide derivatives unique to maca) have structural similarity to endocannabinoid-related compounds and may modulate monoamine pathways. Maca also influences central dopamine and serotonin signaling via its effects on the HPA and hypothalamic-pituitary axes. Co-administration with MAO inhibitors may produce pharmacodynamic interactions including enhanced adrenergic and serotonergic tone, potentially contributing to hypertensive crisis or serotonin-related adverse effects.

Avoid co-administration of maca with MAO inhibitors. If patients on MAOIs report using maca, assess for symptoms of serotonin excess (agitation, tremor, hypertension, hyperthermia, diaphoresis) or hypertensive crisis. Monitor blood pressure regularly and advise on tyramine-rich food interactions in the context of MAOI therapy.